The United States Patent and Trademark Office (USPTO, the Office or the Agency) has recently issued multiple guidance and proposed rules that potentially change the landscape of patent practice.
The Supreme Court’s lone patent case from last term does not break new ground on enablement law. The Court’s core holdings that a patent specification must enable the full scope of the.
Last term, the U.S. Supreme Court did something strange: the Court unanimously affirmed a circuit decision, which had unanimously affirmed a trial court decision. Little about the law seemed ripe for dispute or change, nevertheless, in Amgen v. Sanofi the Supreme Court spoke.
The Court’s rationale in Amgen Inc. v. Sanofi can clear up the decade-long confusion created by Alice Corp. v. CLS Bank Int’l. Enablement and eligibility are entwined, in that both derive from the patent statutes prescribed by Congress.
Patenting Functionally Claimed Biological Compounds After Amgen V Sanofi pharmaceuticalonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmaceuticalonline.com Daily Mail and Mail on Sunday newspapers.